Previous 10 | Next 10 |
Boston, Massachusetts--(Newsfile Corp. - November 15, 2022) - Block & Leviton is investigating Twist Bioscience Corp. (NASDAQ: TWST) for potential securities law violations. Investors who have lost money in their Twist Bioscience Corp. investment should contact the firm to learn more abo...
Twist Bioscience ( NASDAQ: TWST ) plummeted 26% in premarket trading amid a new short report from Scorpion Capital. Scorpion Capital believes that Twist ( TWST ) will go to zero. Twist ( TWST ) short interest is 11%. Twist ( TWST ) didn't im...
Twist Biosciences ( NASDAQ: TWST ) plummeted 26% amid a new short report from Scorpion Capital. Scorpion Capital believes that Twist ( TWST ) will go to zero. Twist ( TWST ) short interest is 11%. Twist ( TWST ) didn't immediately respond to...
Summary Today, we circle back on Twist Bioscience Corporation for the first time since Spring of this year. This unique biology company is delivering stellar sales growth but continues to have significant cash burn issues despite a rock solid balance sheet. An investment analy...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 3...
Twist Bioscience ( NASDAQ: TWST ) and Illumina ( NASDAQ: ILMN ) will partner to expand customer access to the Illumina Exome 2.0 Plus panel to promote disease research. Terms call for Twist ( TWST ) to manufacture the Exome 2.0 Plus panel, wh...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced ...
Twist Biosciences ( NASDAQ: TWST ) announced Wednesday that Patrick Finn is promoted to company's new president and chief operating officer. Finn, who previously served as chief commercial officer, joined Twist in 2015 to build the company’s sales for...
Dr. Finn previously served as Twist’s chief commercial officer Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of ...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...